3-iodobenzylguanidine has been researched along with Apnea, Central in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ando, S; Goto, Y; Kadota, J; Kawano, Y; Kotoku, M; Shinozaki, K; Tamura, A | 1 |
| Adachi, H; Meguro, K; Nagai, R; Ohshima, S; Taniguchi, K; Toyama, T | 1 |
2 other study(ies) available for 3-iodobenzylguanidine and Apnea, Central
| Article | Year |
|---|---|
Washout rate of cardiac iodine-123 metaiodobenzylguanidine is high in chronic heart failure patients with central sleep apnea.
Topics: 3-Iodobenzylguanidine; Aged; Female; Health Status Indicators; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Natriuretic Peptide, Brain; Polysomnography; Prognosis; Radionuclide Imaging; Radiopharmaceuticals; Regression Analysis; Sleep Apnea, Central; Statistics, Nonparametric; Stroke Volume; Sympathetic Nervous System; Ventricular Function, Left | 2010 |
Assessment of central chemosensitivity and cardiac sympathetic nerve activity using I-123 MIBG imaging in central sleep apnea syndrome in patients with dilated cardiomyopathy.
Topics: 3-Iodobenzylguanidine; Aged; Carbon Dioxide; Cardiomyopathy, Dilated; Female; Heart; Humans; Iodine Radioisotopes; Male; Middle Aged; Radionuclide Imaging; Sleep Apnea, Central; Sympathetic Nervous System | 2007 |